Arcus declares cryptic interim win for closely watched anti-TIGIT drug, but you'll have to wait for the data

Big Pharma is racing to carve out an early lead in TIGIT, a potential third immune checkpoint that could offer billions in sales. Roche has led the way there, but small biotech Arcus is advancing its own candidate alongside some big-name partners of their own — and after a mid-stage check-in, the company is going positive with very little on hand to show.